Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A real world study to determine characteristics of treated Idiopathic pulmonary fibrosis patients and impact of antifibrotic treatments in terms of morbidity and mortality in France using data from French RaDiCo Registry

Next Previous
Trial Profile

A real world study to determine characteristics of treated Idiopathic pulmonary fibrosis patients and impact of antifibrotic treatments in terms of morbidity and mortality in France using data from French RaDiCo Registry

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 02 Jul 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nintedanib (Primary) ; Pirfenidone (Primary)
  • Indications Idiopathic pulmonary fibrosis
  • Focus Therapeutic Use
  • Acronyms RaDiCo-ILD registry

Most Recent Events

  • 02 Jul 2020 New trial record
  • 20 May 2020 Baseline characteristics (n=847) of sub-analysis including IPF cohort patients presented at the 116th International Conference of the American Thoracic Society

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top